.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Citi
Mallinckrodt
Novartis
Moodys
Julphar
Argus Health
Accenture
Cantor Fitzgerald

Generated: December 13, 2017

DrugPatentWatch Database Preview

JEVTANA KIT Drug Profile

« Back to Dashboard

Which patents cover Jevtana Kit, and what generic alternatives are available?

Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug.

This drug has two hundred and three patent family members in fifty-eight countries and thirteen supplementary protection certificates in twelve countries.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
Sanofi Aventis UsJEVTANA KITcabazitaxelSOLUTION;IV (INFUSION)201023-001Jun 17, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: JEVTANA KIT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein► Subscribe
5,889,043 Taxoids, preparation thereof and pharmaceutical Compositions containing same► Subscribe
6,387,946 Methods for treating pathological conditions of abnormal cell proliferation► Subscribe
6,593,482 Methods for preparing new taxoids and pharmaceutical compositions containing them► Subscribe
6,331,635 Taxoids, their preparation and pharmaceutical compositions containing them► Subscribe
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
6,232,477 Methods of preparing new taxoids and pharmaceutical compositions containing them► Subscribe
6,187,916 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor► Subscribe
6,040,466 Taxoids, their preparation and pharmaceutical compositions containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JEVTANA KIT

Country Document Number Estimated Expiration
Brazil9607929► Subscribe
World Intellectual Property Organization (WIPO)9630355► Subscribe
TaiwanI533866► Subscribe
European Patent Office0681568► Subscribe
Slovakia90295► Subscribe
New Zealand545835► Subscribe
Greece3031526► Subscribe
Germany69606028► Subscribe
Morocco33767► Subscribe
Eurasian Patent Organization000567► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: JEVTANA KIT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0130017 00077Estonia► SubscribePRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
00595Netherlands► SubscribePRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
C0037France► SubscribePRODUCT NAME: CABAZITAXEL SOUS FORME ACETONATE (OU SOLVAT ACETONIQUE DU CABAZITAXEL); REGISTRATION NO/DATE: EU/1/11/676/001 20110322
/2013Austria► SubscribePRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013000050Germany► SubscribePRODUCT NAME: ACETON-SOLVAT VON CABAZITAXEL; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
90025-3Sweden► SubscribePRODUCT NAME: CABAZITAXEL ACETONSOLVAT; REG. NO/DATE: EU/1/11/676/001 20110317
1 5019-2013Slovakia► SubscribeFIRST REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013010Lithuania► SubscribePRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013010,C1667986Lithuania► SubscribePRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
AstraZeneca
US Department of Justice
Cantor Fitzgerald
Accenture
Cipla
Merck
Chubb
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot